.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AF09_Emtricitabine.Emtricitabine .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AF09_Emtricitabine.Emtricitabine| name: | Emtricitabine |
| ATC code: | J05AF09 | route: | oral |
| n-compartments | 1 |
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) used as an antiretroviral drug in the treatment and prevention of HIV-1 infection. It is often used in combination with other antiretrovirals and is approved for clinical use worldwide.
Pharmacokinetic parameters reported in healthy adult individuals after oral administration of 200 mg emtricitabine.
Valade, E, et al., & Hirt, D (2014). Population pharmacokinetics of emtricitabine in HIV-1-infected adult patients. Antimicrobial agents and chemotherapy 58(4) 2256–2261. DOI:10.1128/AAC.02058-13 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24492366
Dickinson, L, et al., & Boffito, M (2020). Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. The Journal of antimicrobial chemotherapy 75(3) 628–639. DOI:10.1093/jac/dkz479 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31754703
Néant, N, et al., & Solas, C (2018). Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine. European journal of clinical pharmacology 74(4) 473–481. DOI:10.1007/s00228-017-2405-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29374296